The 2026 Approval Class: First-Quarter Launch Report Card

The market pays for the launch, not the approval pop. Six drugs crossed the FDA finish line between July 22 and August 28, 2026, in the busiest approval summer in biotech memory. Four are rounding errors at $50 billion-plus market caps. One is a pure-play royalty stream that moved the stock 15%. One is a first-in-class vaccine that the market already priced in six months ago. This is the 2026 approval class first-quarter launch report card: which approvals matter to the product line, and which matter to the share price.

The 2026 approval scorecard argued earlier this year that the finish line is a mistake: investors buy the approval pop and miss the launch execution. The post-approval first 90 days are when the market separates approvals that drive revenue from approvals that fill PowerPoint slides. The buy-and-bill vs pharmacy benefit economics determine how fast those first 90 days convert to reported revenue. Here is the report card, ranked from highest conviction to lowest.

1. Jideytro (GSK, zidesamtinib): Approved July 22, ROS1+ NSCLC

Jideytro tops the class because it is the simplest: a best-in-class ROS1 inhibitor for a genomically defined lung cancer population where the existing drug (Roche’s Rozlytrek) has a worse safety profile and the next competitor (Turning Point/BMY’s repotrectinib) is already approved but has a different efficacy envelope. GSK acquired Nuvalent for $10.6 billion on July 14 specifically for zidesamtinib’s ROS1 and ALK franchise, and the early approval on July 22 meant the launch started with the full weight of GSK’s oncology commercial infrastructure behind it.

At GSK’s $96 billion market cap and $41 billion in annual revenue, Jideytro’s peak sales of $1.5-2 billion add 3-5% to the top line. That is not a stock-mover at GSK, but it validates the $10.6 billion acquisition thesis within 8 days of closing. If the Q3 earnings call shows a meaningful prescription ramp (500+ patients in the first 10 weeks is the threshold), the Nuvalent acquisition looks shrewd. If Jideytro’s ROS1 launch is soft, the deal overhang weighs on GSK. The Jideytro approval was covered in July; the Q3 print is the launch-grade moment.

2. Mimrylo (Protagonist/Takeda, rusfertide): Approved August 28, Polycythemia Vera

Mimrylo is the only approval in this class where the stock actually moved. Protagonist Therapeutics closed Tuesday at $146.08, up from the mid-$120s before the August 28 FDA approval. Takeda markets the drug; Protagonist gets a tiered royalty stream with Jefferies analysts projecting $2 billion in peak sales.

Rusfertide is a first-in-class hepcidin mimetic that targets the underlying iron dysregulation in polycythemia vera, a chronic blood cancer where overproduction of red blood cells thickens the blood and raises the risk of heart attacks, strokes, and clots. Existing treatment is phlebotomy and hydroxyurea: crude tools that manage hematocrit without addressing the disease mechanism. Mimrylo is a weekly subcutaneous injection that regulates iron distribution and reduces excess red blood cell production.

The launch setup is strong: a clear mechanism story for physicians, a weekly self-administered injection (not an infusion center drug), and a disease where existing standard of care is so inadequate that any new mechanism gets a try. The J-code timing risk is real, as explained in the buy-and-bill guide: newly approved drugs go through a quarterly J-code cycle that can delay reimbursement by 3-6 months. But pharmacy-benefit drugs bypass that cycle, and Mimrylo’s subcutaneous self-administration means it likely routes through the pharmacy benefit. Protagonist at $146 is pricing in a successful launch, not an approval pop. The Mimrylo approval was covered in August.

3. Bixlenvo (Gilead, BIC/LEN): Approved August 27, HIV

Bixlenvo combines bictegravir (the backbone of Gilead’s $14.3 billion Biktarvy franchise) with lenacapavir (the first-in-class capsid inhibitor) into a single daily tablet for virologically suppressed adults. The ARTISTRY Phase 3 program showed noninferiority to Biktarvy. The approval expands treatment choice for patients on complex regimens, particularly those who cannot take currently available single-tablet regimens.

The problem: Gilead is competing with Gilead. Bixlenvo’s target population is patients already on Biktarvy who switch to a newer Gilead pill. That is revenue rotation, not growth. The net new patients come from the complex-regimen population, which is a smaller subset of the 1.2 million Americans living with HIV. Biktarvy generated $14.33 billion in 2025; Bixlenvo’s incremental revenue above Biktarvy’s base is maybe $500-800 million in year one.

At Gilead’s $165 billion market cap, that is sub-1% revenue growth from the launch. The real HIV catalyst is the weekly ISL/LEN pill (islatravir plus lenacapavir, partnered with Merck) with a February 2027 PDUFA. That is the step change in dosing. Bixlenvo is a bridge product. The Bixlenvo approval and the cannibalization thesis were covered in August.

4. Zenbexus (BMY, iberdomide): Approved August 13, Multiple Myeloma

Zenbexus (iberdomide) is the first CELMoD agent, a next-generation cereblon E3 ligase modulator with higher potency than Revlimid and Pomalyst. The FDA granted accelerated approval on August 13 for relapsed/refractory multiple myeloma in combination with daratumumab and dexamethasone, with a confirmatory Phase 3 commitment.

BMY reported Q2 2026 revenue of $12.97 billion, beat consensus by $1.2 billion, and raised 2026 guidance to $49.5 billion. The Growth Portfolio reached 58% of total revenue, growing 15% year-over-year. Zenbexus slots into that portfolio as the Revlimid succession drug: Revlimid sales crashed 49% year-over-year in Q2 to $1.1 billion as generics entered, and Zenbexus is designed to recapture the multiple myeloma franchise.

The launch mechanics are strong: BMY’s existing hematology sales force, established J-codes for the multiple myeloma buy-and-bill channel, and an accelerating approval that caught generic erosion at the right time. But the confirmatory trial overhang is the risk the market is ignoring. Accelerated approvals in multiple myeloma have a mixed confirmatory trial track record: Amgen’s Kyprolis failed its confirmatory trial in 2019 and the FDA considered withdrawal before Amgen ran a second Phase 3. Zenbexus needs a positive confirmatory trial to convert to full approval, and that trial won’t read out for 2-3 years. At BMY’s $137 billion market cap and 2.6x P/S multiple, Zenbexus adds $2-3 billion in peak sales: 5% of revenue. The stock won’t move on this launch; it moves on the Growth Portfolio trajectory as a whole. The BMY Zenbexus approval analysis was covered in August.

5. MFLUSIVA (Moderna, mRNA flu vaccine): Approved August 6, Influenza

MFLUSIVA is the first mRNA flu vaccine, approved for adults aged 50 and older. It is a platform validation milestone: after COVID, Moderna proved mRNA works for a seasonal vaccine with an established regulatory pathway and a pre-existing $6 billion flu vaccine market.

The problem: flu vaccine manufacturing lead times are 6-9 months, and Moderna secured its order book for the 2026-2027 flu season before the August 6 approval. Pharmacies and distributors already committed to Sanofi, GSK, and Seqirus doses for this fall. MFLUSIVA’s first season is a seeding season, not a revenue season: tens of millions in sales, not hundreds. The real commercial test is the 2027-2028 flu season, when Moderna can compete for full-season contracts.

Moderna closed Tuesday at $150.81, down from $167 pre-approval. The market correctly read this: the approval was priced in, and the commercial ramp is a 2027 story, not a 2026 story. MRNA’s Q2 earnings (July 31) guided $2.2 billion in 2026 revenue with an operating loss of $2.4 billion and $6.9 billion in cash, giving 2.5 years of runway. MFLUSIVA approval validates the platform but does not change the cash-burn math in 2026. The Moderna flu vaccine approval was covered in August.

6. Pasatru (Regeneron, garetosmab): Fibrodysplasia Ossificans Progressiva

Pasatru is the second FDA-approved treatment for FOP, an ultra-rare genetic disease where soft tissue progressively turns to bone. The patient population is approximately 800 people in the United States. At Regeneron’s $852 share price and $94 billion market cap, Pasatru is a rounding error: peak sales of $200-300 million on a revenue base of $18 billion.

The launch is not about revenue. It is about maintaining Regeneron’s rare disease credibility and the anti-Activin A mechanism that underlies garetosmab. If the mechanism validates in FOP, it opens the door to other fibrotic indications. But Regeneron’s stock trades on Dupixent ($14.5 billion annualized) and Eylea biosimilar exposure, not on a drug for 800 patients. The Pasatru launch is medically meaningful and financially irrelevant. The Pasatru approval was covered in the approval coverage.

Verdict

Two approvals in this class matter to the share price: Mimrylo for Protagonist and Jideytro for the GSK Nuvalent acquisition thesis. The rest are revenue contributors to mega-cap franchises that won’t move the stock in either direction. Bixlenvo cannibalizes Biktarvy. Zenbexus replaces Revlimid. MFLUSIVA seeds a platform. Pasatru treats 800 patients.

The market pays attention to the wrong moment: the approval pop gets the headlines, but the launch execution gets the revenue. For Protagonist, the Q3 earnings call is the Mimrylo launch report card. If the prescription ramp exceeds 500 patients in the first quarter, the $2 billion peak sales estimate firms up. If not, the approval pop gives back. For BMY and GILD, Zenbexus and Bixlenvo will show up in product-level revenue tables in Q3, and neither will move the stock. The trade in the 2026 approval class is Protagonist on the pure-play launch execution story. Everything else is a dividend-payer holding steady.